7
Cat No. | Product Name | Synonyms | Targets |
---|---|---|---|
T4469 | Nemorubicin | Methoxymorpholinyldoxorubicin,PNU-152243A,PNU 152243 | Others |
Nemorubicin (PNU 152243) is a doxorubicin derivative that differs significantly from its parent drug in terms of spectrum of antitumor activity, metabolism and toxicity profile. The drug is active on tumors resistant to ... | |||
T71467 | Nemorubicin HCL | ||
Nemorubicin HCL is the salt form of Nemorubicin, also known as PNU152243A, a doxorubicin derivative that differs significantly from its parent drug in terms of spectrum of antitumor activity, metabolism and toxicity prof... | |||
T71465 | IDP-73152 | ||
IDP-73152 is a peptide deformylase inhibitor. | |||
T16557 | PNU-159682 | Topoisomerase | |
PNU-159682 is a highly effective metabolite of the anthracycline nemorubicin. PNU-159682 has outstanding cytotoxicity. PNU-159682 is an effective ADCs cytotoxin. | |||
T17802 | DBCO-PEG4-VC-PAB-DMEA-PNU-159682 | Others | |
DBCO-PEG4-VC-PAB-DMEA-PNU-159682, a drug-linker conjugate for antibody-drug conjugates (ADC), comprises the ADC linker DBCO-PEG4-VC-PAB and the potent ADC cytotoxin DMEA-PNU-159682. The cytotoxin includes metabolites of ... | |||
T18302 | Mal-Phe-C4-VC-PAB-DMEA-PNU-159682 | Others | |
Mal-Phe-C4-VC-PAB-DMEA-PNU-159682 is a drug-linker conjugate utilized in antibody-drug conjugate (ADC) therapy. It comprises the ADC linker Mal-Phe-C4-VC-PAB and the potent ADC cytotoxin DMEA-PNU-159682. DMEA-PNU-159682 ... | |||
T18292 | Mal-PEG4-VC-PAB-DMEA-PNU-159682 | Others | |
Mal-PEG4-VC-PAB-DMEA-PNU-159682 is a drug-linker conjugate designed for antibody-drug conjugate (ADC) therapy. It combines the ADC linker, Mal-PEG4-VC-PAB, with the potent ADC cytotoxin, DMEA-PNU-159682. The cytotoxin, D... |